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ABSTRACT : We evaluated the results of cancer therapies rather than surgery in 
167 patients with pancreatic cancer treated at our department during the past 17-year 
period after excluding those with islet cell tumor or cytoadenocarcinoma and those who 
died due to operation. In the group not treated by resection, survival was significantly 
longer in patients treated by combined modality treatment than in those not treated by 
any therapy. Prolongation of the mean survival rate for combined modality treatment 
was more marked in patients with bilio-enteric bypass operation without peritoneal dis-
semination or hepatic metastasis ; the mean survival was 2.6 months in the group not 
treated by any therapy, 6.0 months in that treated by chemotherapy alone, and 7.2 months 
in that treated by combined modality treatment. As anti-cancer drug, 5-FU was the most 
effective. Better results were obtained in patients who received 4,000 rad radiation or 
more than in those who received less than4,000 rads. In the patients who underwent 
resection, better results were obtained in those who underwent combined adjuvant treat-
ment.
       INTRODUCTION 
 Marked advances have been made in the 
diagnosis of pancreatic cancer with a develop-
ment of various tumor markers and improve-
ment in pancreatic imaging techniques such as 
US and CT. However, this disease is rarely 
diagnosed at early curative stages, and in most 
patients, tumors are unresectable or only 
palliative resection are possible. Therefore, 
adjuvant chemotherapy has been used as a 
treatment to prolong the survival period of 
unresectable patients, and even for the patients 
with resectable tumors, adjuvant therapy has 
also been performed to enhance curability. 
However, response rates following single drug 
chemotherapy have been frequently reported to 
be lower in patients with pancreatic cancer than 
in those with cancer of other organs. 
 Therapies such as continuous administration
or high dose regional infusion') of anti-cancer 
drugs and new devices for hypoxic cell radio-
sensitizers2) in radiotherapy, and monoclonal 
antibody target immunotherapy3) are also in 
progress. In addition, systematic treatment that 
combines the effects of each modality including 
chmotherapy, immunotherapy, radiotherapy, 
and hyperthermia has become extremely impor-
tant. We analyzed the results of our combined 
modality approach.
   MATERIALS AND METHODS 
 During the past 17 years, we treated 179 
patients with adenocarcinoma of the pancreas 
(107 males and 72 females). Their mean age was 
60.1 years for males and 59.7 years for famales. 
The tumor was resectable in 41 of the 179 
patients (22.9%) ; pancreatoduodenectomy was 
performed in 20 patients, total pancreatectomy 
in 15, distal pancreatectomy in 9.
               Table 1. Modality of treatment for pancreatic cancer 
                     case surgical chemo. rad. immuno. multimodality                             only only only only treatment 
Resection (41), 
 adenocarcinoma 38 9 17 0 0 12 
 cystadenocarcinma 3 1 1 0 0 1 
Unresectable (126) 
 adenocarcinoma 121 27 60 2 5 27 
 cystadenocarcinoma 3 3 0 0 0 0 
 others 2 1 0 0 0 1
 Of 38 patients who underwent resction, 
chemotherapy alone was performed as adjuvant 
therapy in 17. Two adjuvant therapies or more 
were combined in 12 (combined modality 
treatment group), but adjuvant therapy was not 
performed in 9. Of 121 patients who did not 
undergo resection, 67 received either chemo-
therapy, radiotherapy, or immunotherapy alone, 
and 27 were treated by combination of these 
therapies (Table 1). The results of these 
treatments were compared by using mean 
survival period, and the differences were 
assessed by Wilcoxon test.
          RESULTS 
1. Unresectable Pancreatic Carcinoma 
 Chemotherapy alone was performed in 60 
patients, of whom 37 received single durg 
chemotherapy and the remaining 23 were treated 
by combination chemotherapy. Of the patients 
who were treated by single drug chemotherapy, 
a fluoroprymidine derivative, primarily 5-fluoro-
uracil (5-FU) was used in 22 patients, 
Neocacinostatin (NCS) in 7, and Mitomycin C 
(MMC) in 8. In the patients treated by 
combination chemotherapy, 5-FU was most 
frequentyly given in combination with NCS, 
MMC, Endoxan, or Adriamycin. The mean 
survival period of single drug treatment was 5.5 
months in the patients with 5-FU, 2.3 months 
in those with MMC, and 2.9 months in those 
treated with NCS. 5-FU showed the most 
longest mean survival period among these 
drugs, but no significant defference was seen. 
No significant difference was also present 
between the patients treated by single 
chemotherapy and those treated by combination 
chemotherapy (Table 2).
 Radiotherapy was performed on 17 patients 
in a dose ranging from 1,350 to 6,950 rads (mean 
3,740 rads). Of them, 11 also received chemo-
therapy and 4 underwent chemotherapy plus 
immunotherapy with OK432 (picibanil) or PSK 
(Krestin). The mean survival period in 8 
patients who received less than 4,000 rads was 
4.0 months, but 6.8 months in 9 who received 
more than 4,000 rads (Table 3). 
 Immunotherapy was performed in 21 patients. 
Of them, 5 were treated by immunotherapy only. 
Chemotherapy was combined in 11, and 
chemotherapy plus radiotherapy were combined 
in 5. The mean survival period was almost same 
between the patients treated by immunotherapy 
alone and those treated in combination with 
chemotherapy, but longer in those with 
chemotherapy and raiotherapy. The mean
Table 2. Results of chemotherapy for unresectable 
         pancreatic cancer 
                        no. mean survival 
                      case period (mos.)
single Use 37 4.7±4.7 
   5-FU 22 5.5±5.9 
   MMC 8 2.3±1.0 
   NCS 7 2.9±1.2 
combination use 23 3.9±2.3
Table 3. Result of ratiation therapy for unresec-
        table pancreatic cancer 
                               no. mean survival 
                          case period (mos)
radiation only 2 5.0±1.0 
rad.+single chemererapy 7 4.4±3.4 
rad.+combination chemo. 4 5.3±3.5 
<4,000 rad 8 4.4±1.3 
>4,000 rad 9 6.9±2.3
survival period was 5.7 months in patients 
treated with PSK and 3.1 months in those 
treated with OK432. PSK treated group showed 
a significant longer mean survival period as 
compared with that of OK432 group (p<0.05). 
The mean survival period in 2 patients treated 
both with OK432 and PSK was 8.5 months (Table 
4).
Table 4. Result of immunotherapy for unresctable 
         pancreatic cancer 
                           no. mean survival 
                      case period (mos)
immunotherapy only 5 4.4±2.8 
immuno.+chemothrapy 11 4.4±2.6 
immuno.+chemo.+radio. 5 5.3±3.2 
OK432 10 3.0±2.1 
PSK 9 5.7±2.1 
both 2 8.5±2.5
treatment on adjuvant therapy from evaluation 
of these results, survival was compared in the 
patients who underwent bilioenteric bypass 
operation for those locally advanced but without 
liver and peritoneal involvement (PoHo). The 
mean survival was 2.6 months in patients not 
treated by any adjuvant therapy. 6.0 months 
in those treated by chemotherapy alone, and 7.2 
months in those treated by multi-modality 
treatment. Multi-modality treatment group 
showed a significantly longer survival (p<0.01) 
than the group not treated by any therapy (Fig. 
2).
 The therapeutic effects were compared among 
the patients, without any therapy, with 
chemotherapy alone, and with multi-modality 
treatment. The mean survival was 2.7 months 
in 27 patients without any therapy, 4.1 months 
in 60 patients who received chemotherapy alone, 
and 4.9 months in 27 patients who received 
multi-modality treatment. The patients with 
multimodality treatment showed a significantly 
higher cumulative survival rate than those of 
not treated by any therapy during the period 
between the 3rd and 6th months (p<0.05) and 
than those treated by chemotherapy alone at the 
3rd month (Fig. 1). 
 To exclud the infuencec of palliative surgical
Fig. 1.
Fig. 2.
2. Resectable Pancreatic Cancer 
 In the 38 patients who underwent resection, 
the mean survival was 7.8 months in 9 patients 
without any adjuvant therapy, 16.2 months in 
those treated by single chemotherapy, and 15.4 
months in 12 patients treated by combined 
adjuvant therapy. A significant difference was 
observed between the group treated by 
chemotherapy and that not treated by adjuvant 
therapy. However, no significant difference was 
observed between the group treated by 
combined adjuvant therapy and that without 
any adjuvant therapy (Fig. 3). 
 In patients with curative resection, the mean 
survival was 6.2 months in 3 not treated by 
adjuvant therapy, 26.1 months in 12 patients 
treated by immunochemotherapy, and 41.3 
months in 2 patients treated by multi-
modality therapy. A significant difference was 
observed in the patients of curative resection 
between the group with and without adjuvant 
therapy in survival during the period of from
Fig. 3.
Fig. 4.
                Table 5. Mean survival period in resected case 
                  Multimodality Immunochemo. Radiation no adjuvant 
curative (n=17) 41.3mos 26.1±26.0 - 6.2±5.0 
                    (n = 2) (n = 12) (n=3) 
noncurative (n=35) 9.2±5.4 8.6±5.2 8.2 8.3±6.5 
                   (n=9) (n=13) (n=2) (n=11)
3 months to 13 months (Table 5, Fig. 4).
         DISCUSSION 
 Since tumor is resectable, at present, only 
about in 30% of the patients with pancreatic 
cancer and curative resection in less than 10%, 
hope is placed in the effects of additional 
ajuvant therapy such as chemotherapy, 
radiotherapy, immunotherapy, or microwave 
hyperthermia. Harvery et a14) reported in their 
review of the literature that only Streptozotocin, 
5FU, and MMC showed respectively more than 
20% response rates, but Adriamycin, NCS, 
Methyl-CCNU, and Cis-platinum showed only 
about 10% response rates. However, other 
reported response rates varied even with 5FU. 
Stolinsky5) compared the effects of 5-FU 
between oral and intravenous administration, 
and observed higher response rates following 
intravenous administration. This date suggest 
that therapeutic effects seem to be associated 
with the doses and modes of administration. 
 We also used fluorapyrimidines, especially 
5-FU, most frequently. The mean survival 
period in the patients treated with 5-FU revealed 
about two times longer than that in the patients
treated with MMC or NCS. Fluoropyrimidine 
was suggested to be the most effective 
anti-cancer because back ground factors of the 
patients did not differ between these 3 drug 
groups. 
 MMC is the second most commonly used drug 
for pancreatic cancer. The response rates with 
this drug were reported to be 27%6). However, 
this drug has strong side effects such as 
myelosuppression, and the most of the patients 
with pancreatic cancer usually showing poor 
Perfomans Status can not tolerate adequate 
dose that may produce clinical anti-cancer 
effects. Among nitrosoureas, the response rates 
in patients with pancreatic cancer were reported 
to be 16% with CCNU, 6% with Methyl-CCNU'), 
and 13% with Adriamicin used for the initial 
treatment'). DuPriest et al.9) reported that the 
response rates following single chemotherapy 
with Streptozotocin were 36% in patients with 
adenocarcinoma of the pancreas, but we did not 
have any experience of this drug. 
 To enhance therapeutic effects of chemo-
therapy for advanced pancreatic cancer com-
bination of drugs with different mechanisms of 
action was used in the treatment. Wiggans et 
aL10) treated 23 patients with Streptozotocin+
MMC+5FU+(SMF therapy) and observed 48% 
responce (CR 1 patient, PR 9 patients). Smith 
et al.1'> treated 27 patients with 5FU+ 
Adriamycin+MMC (FAM therapy) and obtained 
PR in 37% (10 patients). Mallinson et al. 12> 
reported the mean survival of 44 weeks in 
patients treated by combination chemotherapy 
(5FU + Cyclophosphamide + Methotrexate + 
Vincristine+MMC), but 9 weeks in control 
group. These studies strongly suggest the 
efficacy of combination chemotherapy as a 
treatment of pancreatic cancer. However, in 
contrast, Cullinan et al. 13> failed to show any 
advantage of combination chemotherapy when 
compared among the groups treated with 5-FU 
alone, 5-FU+doxorubicin, and 5-FU+doxoru-
bicin+MMC. 
 Recently, usefulness of intraoperative irradia-
tion developed by Abe et al.14> has been 
evaluated actively. Komaki et al. 15> performed 
external irradiation for the patients with unre-
sectable pancreatic cancer without distant 
metastasis and observed a median survival of 
7 months in patients who received less than 4,500 
rads and a median survival of 13 months in 
those who received 4,500 rads or more. Shipley 
et al.") perfromed intraoperative irradiation in 
combination with external irradiation in 
patients with unresectable pancreatic cancer 
and reported a median survival of 16. 5 months. 
Similar effects of radiotherapy were reported in 
the Western countries.",") Shipley et a1.19> also 
observed high local control rates following local 
implantation of 13I needles. Gunderson et al.20' 
showed inhibitory effects of small doses 
preoperative irradiation on peritoneal seeding 
and preventive effects in combination of 
chemotherapy on distant metastasis. Cohen et 
al.21> and Sindelar et al.22> histologically 
evaluated the effects of radiotherapy and 
demonstrated marked reactive fibrosis in and 
around the tumor lesion. We recognized direct 
effects of irradiation on tumors, and also 
observed symptomatic improvements in general 
condition such as increased appetite resulting 
from relief of pain, which would be 
contributable to prolong survival. However, 
most of the patients treated by irradiation were 
HoPo patients and usually performed in 
combination with chemo- or immunotherapy,
therefore it was difficult to evaluate true effect 
on pancreatic cancer. 
 A randomized study conducted by the Gastro-
intestinal Tumor Study Group (GITSG)23' that 
compares the therapeutic effects between 
patients treated by irradiation alone and those 
treated by irradiation+5FU chemotherapy 
showed prolongation of survival following the 
combined modality treatment. Kalser et al.L4' 
reported the mean survival in the group treated 
by irradi ation+chemotherapy (20 months) was 
significantly longer than that in the control 
group (10 months). Similar results were seen 
in our patients. 
 As the effects of PSK, a non-specific 
immunoactivator, Ebina et al.25' showed the 
possibility that immunoactivator inhibits tumor 
proliferation at distant sites. In our patients 
treated with PSK, survival was singificantly 
prolonged, but further evaluation is needed in 
additional patients.
         REFERENCES 
1) Theodors A, Bukowski R, Hewlett S, Livingston 
   RB, Weick JK.: Intermittent regional infusion 
   chemotherapy for pancreatic adenocarcinoma. 
  Am J Clin Oncol 5:555-558, 1982 
2) Ono K, Komura C, Nishidai T, Shibamoto Y, 
  Tsutsui K, Takahashi K, Abe M.: Radio-
   sensitizing effect of misonidazole in combinztion 
  with an inhibitor of glutathione synthesis in 
   murine tumor. Int J Radiation onocology Biol Phys 
  12:1661-1666, 1986 
3) Sears HF, Herlyn D, Stepleweski Z. Koprowski 
   H.: Phase II clinical trial of a murine monoclonal 
   antibody cytotoxic for gastrointestinal adeno-
   carcinoma. Cancer Res 45: 5910-5913, 1958. 
4) Harvey, JH. Schein PS.: Chemotherapy of 
   pancreatic carcinoma. World J Surgery 8: 935-
  939, 1984. 
5) Stolinsky, DC. Pugh, RP. Bateman JR.: 5-FU 
   therapy for pancreatic carcinoma : comparision 
   of oral and intravenous routes. Cancer Chemo-
   ther. Rep. 59: 1031, 1975. 
6) Zimmerman, SE. Shimitb F, Schein P.: Chemo-
   therapy of pancreatic carcinoma. Cancer 47: 
  1724-1728, 1981. 
7) O'Connell, MJ.: Current status of chemo-
   therapy for advanced pancreatic and gastric 
   cancer. J. Clin. Oncol 3:1032-1039, 1985.
8) Gastrointestinal Tumor Study Group. Ran-
   domized phase II clinical trial of adriamycin, 
   methotrexate, and actinomycin D in advanced 
   mesaurable pancreatic carcinoma. Cancer42 : 19-
  22, 1978. 
9) DuPriest RW, Huntington MC, Massey WH, 
   Weiss AJ. Willson WC, Fletcher WS.: 
   Streptozotocin therapy in 22 Cancer Patients. 
   Cancer 35: 358-365, 1975 
10) Wiggans RG, Woolley PV, Macdonald JS, 
   Smythe T, Ueno W, Schein PS.: Phase II trial 
   of streptozotocin, mitomycin C and 5-fluorou-
   racil (SMF) in the treatment of advanced 
   pancreatic cancer. Cancer 41 : 387-391, 1978. 
11) Smith FP, Hoth DG, Levin B, Karlin DA, 
   Macdonald JS, Woolley PV, Schein PS.: 
   5-fluorouracil, adriamycin and mitomycin-C 
   (FAM) chemotherapy for advanced adeno-
   carcinoma of the pancrea Cancer 46: 2014-2018, 
  1978 
12) Mallison CN, Rake MO, Cocking JB, Fox CA, 
   Cwynarski MT, Diffey BL, Jakson GA.: 
   Chemotherapy in pancreatic cancer : results of 
   a controlled, prospective, randomized, multi-
   centre trial. Brit. Med. J. 281 :1589-1591, 1980. 
13) North Central Cancer Treatment Group : Com-
   parison of three chemotherapeutic regiments in 
   the treatment of advanced pancreatic and
   gastric carcinoma fluorouracil vs fluorouracil 
   and doxorubicin vs fluorouracil, doxorubicin 
  and mitomycin. JAMA 253:2061-2067, 1985 
14) Abe M, Takahashi M, Yabumoto E, Onoyama 
   Y, Torizuka K, Tobe T, Mori K.: Techniques, 
   indications and results of intraoperative 
   radiotherapy of advanced cancers. Radiology 
  116:693-702, 1975. 
15) Komaki R, Willson JF, Cox JD, Kline RW.: 
   Carcinoma of the pancreas : results of 
   irradiation for unresectable lesions. Int. J. 
  Radiology Biol. Phys. 6:209-212, 1980. 
16) Shipley, MU.: Intraoperative electron beam 
  irradiation for patients with unresectable 
   pancreatic carcinoma. Ann. Surg. 200:289-294, 
  1984.
17) Moertel, CG.: Advanced gastrointestinal cancer: 
   Management and chemotherapy. New York, 
   Harper & Row, 1969. pp 3-14. 
18) Tepper J, Naradi G, Suit H.: Carcinoma of the 
   pancreas : Review of MGH experience from 1963 
   to 1973. Cancer 37: 1519-1524, 1976. 
19) Shipley, WU. Tepper JEW arshaw AL, Orlow 
   EI: Intraoperative radiation therapy for patients 
   with pancreatic carcinoma. World) Surg. 8 : 929-
  934, 1984. 
20) Gunderson LL, Martin JK, Oconnell MJ, Beart 
   RB, Kvols LK, Nagorney DM.: Residual, 
   recurrent, or unresectable Gastrointestinal 
   Cancer. Role of radiation in single or combined 
   modality treatment. Cancer 55: 2250-2258, 1985. 
21) Cohn, L.: Response of pancreatic cancer to local 
   irradiation with high-energy neutrons. Cancer 
  56: 1235-1241, 1985. 
22) Sindelar WF, Hoekstra H, Restrepo C, Kinsella 
   TJ.: Pathological tissue changing following 
   intraoperative Radiology. Am J Clin Oncol 9: 
  504-509, 1986 
23) The gastrointestinal Tumor Study Group : 
   Therapy locally unresectal pancreatic carci-
   noma : A randomized comparison of high dose 
   (6000rads) radiation alone, moderate dose 
  radiation (4000rads+5-fluorouracil), and high 
   dose radiation +5-fluorouracial. Cancer 48 : 1705-
  4710, 1981. 
24) Kasler MH, Ellenderg SS.: Pancreatic cancer, 
   adjuvant combined radiation and chemotherapy 
   following curative resection. Arch Surg 120: 899-
  903, 1985. 
25) Ebina T, Kohya H.: Antitumor effect of PSK 
   (2) : effector mechanism of antimetastatic effect 
   in the "double grafted tumor system" Jpan J 
   Cancer Chemothr 14:1847--1853, 1987.
